Earnout provisions are common in life sciences and healthtech mergers and acquisitions, particularly when an acquired company may add significant value after closing. This can occur if the acquired business has a product in...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2023 include:
Life sciences VC deal value in Q3 2023 totaled $7.7 billion, representing an uptick from last quarter...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2022 include:
• Deal value reached $7.1 billion in Q4 across 392 deals, bringing the 2022 annual total to $38.0 billion...more
This edition of Orrick’s life sciences publication series breaks down the key drivers of venture investment in the life sciences industry during Q1 2022, which saw some disruptions following a record year in 2021.
Key...more
This edition of Orrick’s life sciences publication series breaks down the key drivers of venture investment in the life sciences industry, which is on track to set all-time records this year. Key findings include: • With...more